Caliper launches unique in vivo imaging system
company's suite of in vivo imaging systems promising
advanced fluorescent detection capability for accelerating the drug
discovery and development process reducing cost and time in the
process.
The latest addition is in keeping with the company's line of non-invasive imaging systems that enable scientists to better visualise, track and understand biological processes in living animals in real time at a molecular level.
Illuminating biological processes allows real-time visual exploration and analysis of gene expression, cellular pathways, drug/target interactions and the mechanism of action of drugs.
According to Caliper, the Xenogen IVIS Spectrum, is the only in vivo optical imaging system that can perform high sensitivity bioluminescent imaging and advanced fluorescent imaging, including spectral unmixing, trans-illumination, and 3D tomographic capabilities.
With an optical switch to move from epi- (reflection or top illumination) to trans-illumination (bottom illumination), IVIS Spectrum maintains high throughput capability, while providing increased sensitivity in fluorescent imaging.
In addition, the dual illumination capability enables tomographic localisation of both shallow and deep tumours in 3D reducing background interference.
Spectral unmixing, using discrete bandpass filters, reduces background autofluorescence and allows separation of multiple reporters.
"Caliper is committed to pioneering highly innovative and transformative technologies that meet the needs of the research and development community," said Kevin Hrusovsky, president and CEO of Caliper.
"The IVIS Spectrum is a translational tool that enables both superior fluorescent and bioluminescent capabilities and is designed to improve productivity and clinical relevancy through the entire continuum of drug discovery."
The IVIS Spectrum taps into an emerging research trend that has seen a shift from basic to more applied clinical work that steps up from single cell analysis to increasingly complex tissues and whole body imaging.
With a full range of optical filters for imaging any probe/reporter in the visible to near-infrared part of the spectrum, and a flexible lens system that provides both high resolution (down to 20 microns) and high throughput with 25 cm field of view, the new system is designed to enable researchers to more accurately pinpoint where and when a drug candidate has an effect on or is affected by a normal or disease process.
